This appeared to be due to the opinion of the people presenting the case that there was not enough evidence to suggest that this had any benefits at all for patients, there was even a question posed (by Dr Leighton) as to whether this procedure might be more dangerous for people with MS.One interesting piece of information was revealed: Charing Cross are doing an in depth evaluation of Doppler efficacy for the diagnosis of CCSVI.
Dr Alasdair Coles, the Neurologist adviser to the Association of British Neurologists presented as a caring and patient aware person who acknowledged that there was a vascular history to MS but that he had no evidence that this caused MS neurological symptoms.
Although, when asked, he did not disclose any interest we found out later that his research is actually funded by a couple of pharmaceutical companies and he works with the MS Society advisor Alastair Compston.Although the topic they were discussing was quintessentially about circulatory problems, no mention was made about the vascular symptoms that certain MS patients experience.
In the end the committee felt that there was not enough evidence to go on and they thought that a recommendation of RCT would be the best way forward and that two or three years down the line they might have enough evidence on which to make a decision. Monica Leighton thought that evaluation should be based on clinical and quality of life criteria, and that research projects should define technical success and measure gradients across strictures.
We were disappointed at the inaccuracies and omissions which could have easily been rectified by at least four of the observers sitting at the back of the room who incidentally were the hosts of the Glasgow Conference. We think it is important that we all take every opportunity to comment on the process which took place, on the outcome of this meeting and voice our opinions as to what should happen next.
Lobby -Midcity Place